Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss
of retinal ganglion cells and their axons. It is an irreversible disease with no established …

OBJECTIVE: To estimate the intraocular pressure (IOP) reduction achieved by the most
frequently prescribed glaucoma drugs and a placebo in a meta-analysis of randomized …

Primary open-angle glaucoma, a long-term degenerative ocular neuropathy, remains a
significant cause of vision impairment worldwide. While many risk factors have been …

Glaucoma is a major cause of irreversible blindness in the world. The prevalence of
glaucomatous loss in vision will continue to grow as our populations age. Ocular …

Glaucoma, a leading cause of blindness worldwide, is a chronic neurodegenerative
disorder. Patients with glaucoma may require long-term administration of intraocular …

Glaucoma is a multifactorial optic neuropathy in which there is a characteristic acquired loss
of retinal ganglion cells, at levels beyond normal age-related baseline loss, and …

Intraocular pressure (IOP) reduction is currently the only therapeutic approach demonstrated
to preserve visual function in patients with glaucoma. The first line of glaucoma treatment …

The future of next generation therapeutics for glaucoma is strong. The recent approval of two
novel intraocular pressure (IOP)-lowering drugs with distinct mechanisms of action is the first …

Glaucoma is a complex condition of the eye. It is an ophthalmic neurodegenerative condition
and is characterised by raised intraocular pressure. When left untreated, patients may …

Glaucoma is one of the leading causes of blindness worldwide. Increased intraocular
pressure (IOP) is considered to be the most important risk factor. Major outcome studies from …